Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The National Health Service named Oxford Vaccine Group’s Meningitis B vaccination programme one of the 70 most transformative discoveries over the past 70 years.

July 2018 marks the 70th birthday of the National Health Service. As part of the celebrations, the NHS’s I Am Research campaign highlights the research achievements that have improved health and care over the past 70 years, and shows how the work of National Institute for Health Research is helping to shape the future. Drawing on suggestions of experts from across the NIHR, the campaign presents 70 discoveries that have been the most transformative for both the NHS and its patients.

The Department of Paediatrics is very pleased that the Meningitis B vaccination programme featured among the 70 discoveries – particularly since the Oxford Vaccine Group administered the very first paediatric dose of the vaccine!

Meningococcal disease is caused by the bacterium Neisseria meningitidis, and can lead to meningitis (inflammation of the membranes that surround the brain) and septicaemia (blood poisoning). Meningitis B accounts for about 90% of meningococcal infections in the UK, each year there are between 500 and 1700 cases. It can affect all age groups, but the rates of disease are highest in children under five years of age, and most cases are seen in babies under the age of one. It is also often seen in teenagers aged between 15 and 19.

Introduction of the Meningitis B vaccination programme has seen cases in infants aged one or less drop by 42%. Currently Oxford Vaccine Group is leading another a study aimed at an older age group, investigating whether giving a MenB vaccine to teenagers reduces carriage of this bacteria, potentially providing protection to all ages from this dangerous infection.

If you would like to take part in the Be on the TEAM (TEenagers Against Meningitis) study, please take a look at the project website.


Similar stories

New trial launches for two-in-one vaccine to prevent RSV and hMPV

Scientists at the University of Oxford have launched a phase 1 study to test two investigational mRNA vaccines: one for both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and a second for RSV alone in infants aged five to eight months old. The vaccines are being developed by Moderna.